Our Experience in Hepatoblastoma Surgery
Objective: In this study, we aimed to present our patients with hepatoblastoma who had undergone surgery. Materials and Methods: The patients who had been operated for hepatoblastoma in the last ten years at Çukurova University Hospital were included in the study. The age, gender, complaints, blood alpha-fetoprotein level, whether neoadjuvant chemotherapy was administered, size, stage, surgical findings, distant metastasis, postoperative complications, outcome, and mortality were assessed. Results: We operated on 22 patients with hepatoblastoma in the last ten years. We could access data of 17 patients. The mean age of the patients was 22 months (4-96 months). 88% of the patients were aged younger than 5 years and 76% younger than 3 years. Seven patients were male, and ten were female. Fourteen patients presented with abdominal distention and swelling. One patient was admitted to the hospital with weight loss, one with diarrhea and one with a fever. In the first evaluation, eight patients were in stage 2 and nine in stage 3 according to the PRETEXT staging. We did not have any stage 1 or 4 patients. Alpha-fetoprotein level levels were high in 16 patients. The mean size of the mass was 11.5 cm at the first evaluation. One patient underwent surgery for trans-arterial chemoembolization since the tumor could not be excised after chemotherapy; we were able to excise the tumor totally following trans-arterial chemoembolization. Two patients had portal vein thrombosis and one was excised during surgery. Seven patients had undergone right, three patients right-expanded, three patients left-expanded, one patient segmental 6-7, and three patients left hepatectomy. Distant metastases were present in two patients (lungs). Mortality occurred in one patient. Conclusion: Multidisciplinary approach is fundamental in hepatoblastoma and other malignant masses. Not only pediatric oncology but also alternative treatment options such as trans-arterial chemotherapy should be considered.
___
[1] Chen WJ, Lee JC, Hung WT. Primary malignant tumor of liver in infants and children in Taiwan. J Pediatr Surg 1988; 23(5): 457-61.[2] Ni YH, Chang MH, Hsu HY, et al. Hepatocellular carcinoma in childhood. Clinical manifestations and prognosis. Cancer 1991; 68(8): 1737-41.
[3] Aronson DC, Czauderna P, Maibach R, et al The treatment of hepatoblastoma: Its evolution and the current status as per the SIOPEL trials. J Indian Assoc Pediatr Surg 2014; 19(4): 201-07.
[4] Sunil BJ, Palaniappan R, Venkitaraman B, et al. Surgical Resection for Hepatoblastoma-Updated Survival Outcomes. J Gastrointest Cancer 2018; 49(4): 493-96.
[5] Czauderna P, Otte JB, Aronson DC, et al. Guidelines for surgical treatment of hepatoblastoma in the modern era--recommendations from the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL). Eur J Cancer 2005; 41(7): 1031-36.
[6] Czauderna P, Lopez-Terrada D, Hiyama E, et al. Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy. Curr Opin Pediatr 2014; 26(1): 19-28.
[7] Clavien PA, Barkun J, de Oliveira ML, et al. The ClavienDindo classification of surgical complications: five-year experience. Ann Surg 2009; 250(2): 187-96.
[8] Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240(2):205-13.
[9] Douglass EC, Green AA, Wrenn E, et al. Effective cisplatin (DDP) based chemotherapy in the treatment of hepatoblastoma. Med Pediatr Oncol 1985; 13(4):187-90.
[10] Darbari A, Sabin KM, Shapiro CN, Schwarz KB. Epidemiology of primary hepatic malignancies in U.S. children. Hepatology 2003; 38(3): 560-66.
[11] Agarwala S, Gupta A, Bansal D, et al. Management of Hepatoblastoma: ICMR Consensus Document. Indian J Pediatr 2017; 84(6): 456-64.
[12] Ortega JA, Douglass EC, Feusner JH, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children’s Cancer Group and the Pediatric Oncology Group. J Clin Oncol 2000; 18(14): 2665-75.
[13] Couinaud C. [Liver lobes and segments: notes on the anatomical architecture and surgery of the liver ]. Presse Med 1954; 62(33): 709-12.
[14] Black CT, Cangir A, Choroszy M, et al. Marked response to preoperative high-dose cis-platinum in children with unresectable hepatoblastoma. J Pediatr Surg 1991; 26(9): 1070-73.
[15] Otte JB, Meyers R. PLUTO first report. Pediatr Transplant 2010; 14(7): 830-35.
[16] Guerin F, Gauthier F, Martelli H, et al. Outcome of central hepatectomy for hepatoblastomas. J Pediatr Surg 2010; 45(3): 555-63.
[17] De Ioris M, Brugieres L, Zimmermann A, et al. Hepatoblastoma with a low serum alpha-fetoprotein level at diagnosis: the SIOPEL group experience. Eur J Cancer 2008; 44(4): 545-50.
[18] Busweiler LA, Wijnen MH, Wilde JC, et al. Surgical treatment of childhood hepatoblastoma in the Netherlands (1990-2013). Pediatr Surg Int 2017; 33(1): 23-31.
- ISSN: 2147-9488
- Yayın Aralığı: Yılda 4 Sayı
- Başlangıç: 2012
- Yayıncı: HACETTEPE ÜNİVERSİTESİ
Sayıdaki Diğer Makaleler
Gamze DURHAN, Ömer ÖNDER, Aynur AZİZOVA, Jale KARAKAYA, Kemal KÖSEMEHMETOĞLU, Meltem Gülsüm AKPINAR, Figen DEMİRKAZIK
Süreyya TALAY, Nahide BELGİT TALAY
Özlem DİKMETAŞ, Bogomil VOYKOV
Our Experience in Hepatoblastoma Surgery
Önder ÖZDEN, Şeref Selçuk KILIÇ, Abdullah ÜLKÜ, Gülay SEZGİN, Recep TUNCER
Evaluation of the Effectiveness of Tenofovir in Chronic Hepatitis B Patients
Seval Müzeyyen ERCİN, Nursel ÇALIK BAŞARAN, Murat ALADAĞ
The Impact of Noise on Hearing in Intensive Care Unit Nurses
Süheyla ABİTAĞAOĞLU, Alev ÖZTAŞ, Fatma ŞİMŞEK CEVİZ, Ceren KÖKSAL, Tuğba ASLAN DÜNDAR, Güldem TURAN, Dilek ERDOĞAN ARI